ALVR
NASDAQAlloVir Inc.
AlloVir Inc. (ALVR) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for ALVR in the last 30 days. The most recent was published Mar 27, 2025.
Latest news
25 items- INSIDERChief Accounting Officer Hagen Brett R sold $8,135 worth of shares (907 units at $8.97), decreasing direct ownership by 32% to 1,925 units (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERAmendment: New insider Akkaraju Srinivas claimed ownership of 3,578 shares (SEC Form 3)3/A - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form SCHEDULE 13D filed by AlloVir Inc.SCHEDULE 13D - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERNew insider Samsara Biocapital Gp, Llc claimed ownership of 11,448,081 shares (SEC Form 3)3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERDirector Ferrara Napoleone was granted 504,000 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERDirector Patel Samir Chandrakant was granted 352,800 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERChief Medical Officer Feinsod Matthew was granted 4,030 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Officer Oxtoby Andrew4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERDirector Akkaraju Srinivas was granted 11,444,503 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Director Adamis Anthony P4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Akkaraju Srinivas3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ferrara Napoleone3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dybbs Michael3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Patel Samir Chandrakant3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Oxtoby Andrew3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Feinsod Matthew3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 3 filed by new insider Adamis Anthony P3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECAlloVir Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Leadership Update, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Regulation FD Disclosure8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by AlloVir Inc.8-K - Allovir, Inc. (0001754068) (Filer)
- SECSEC Form 10-K filed by AlloVir Inc.10-K - Allovir, Inc. (0001754068) (Filer)
- SECSEC Form 424B3 filed by AlloVir Inc.424B3 - Allovir, Inc. (0001754068) (Filer)
- INSIDEROfficer Sinha Vikas sold $3,053 worth of shares (303 units at $10.08), decreasing direct ownership by 0.61% to 49,129 units (SEC Form 4)4 - Allovir, Inc. (0001754068) (Issuer)
- INSIDERGeneral Counsel Miller Edward sold $1,068 worth of shares (106 units at $10.08), decreasing direct ownership by 2% to 6,517 units (SEC Form 4)4 - Allovir, Inc. (0001754068) (Issuer)
- INSIDERChief Accounting Officer Hagen Brett R sold $967 worth of shares (96 units at $10.08), decreasing direct ownership by 3% to 2,832 units (SEC Form 4)4 - Allovir, Inc. (0001754068) (Issuer)
ALVR FAQ
8 questionsWhat does AlloVir Inc. do?
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2...What is the latest news on ALVR?
Quantisnow has not tracked any new filings, ratings or press releases for ALVR in the last 30 days. The most recent wire item was published on March 27, 2025.Where does ALVR stock trade?
AlloVir Inc. (ALVR) is listed on NASDAQ.What sector and industry is ALVR in?
AlloVir Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did AlloVir Inc. go public?
AlloVir Inc. (ALVR) completed its IPO in 2020.What are analysts saying about ALVR?
Across the last 8 analyst actions on AlloVir Inc., there were 0 upgrades and 4 downgrades. The most recent action was from BofA Securities: Underperform with a $1.00 price target on 2023-12-26.What companies are similar to ALVR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ALVR side-by-side with any of them on Quantisnow.How can I track ALVR on Quantisnow?
Quantisnow aggregates AlloVir Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALVR to receive live email and push alerts on every new disclosure.